Leveraging proven antiviral strategies, OpenBind unites global pioneers in AI and structural biology to revolutionise drug discovery – creating preclinical candidates and vast open datasets that accelerate innovation worldwide
is a Principal Scientist at Diamond and Professor of Structural Biology at the Oxford Centre for Medicines Discovery. Frank has played a major role in multiple major open data / open science efforts—including the Structural Genomics Consortium (SGC), the COVID Moonshot, Fragalysis, EUbOPEN, and the ASAP Discovery Consortium. As part of ASAP, his group has collected >26,000 crystallographic datasets.
is a Professor at Columbia University. His laboratory is at the frontier of structure-enabled machine learning for drug discovery. He leads OpenFold, a fully open source alternative to AlphaFold that has already moved beyond it in several important ways, and is behind the Genie diffusion models for protein design. He has been heavily involved in blind challenges such as CASP, and has been prominent in this field for some time.
is Director for the Centre for Medicines Discovery at the University of Oxford. His research group works at the interface of chemistry and biology to design probes and inhibitors to investigate the intricate workings of human proteins and cells, with particular interest in epigenetic proteins, small GTPases, and dementia. Research interests include medicinal chemistry, fragment- and structure-based drug design, computational chemistry, organic synthesis, and biochemistry. The group is part of the Alzheimer's Research UK Oxford Drug Discovery Institute (ODDI), and Centre for AI in Precision Medicine at the University of Oxford.
is a Member and laboratory head at the Memorial Sloan Kettering Cancer Center. He currently leads the NIH-funded open science ASAP Discovery Center, and the computational arm of the ARPA-H funded OpenADMET project. He has spent his career producing open data and open source software tools for accelerating drug discovery, and launched multiple sustainable software projects hosted at the Open Molecular Software Foundation (OMSF), He is a member of the Folding@home Consortium and co-founded the COVID Moonshot open data drug discovery project.
is the co-founder and Executive Director of the Open Molecular Software Foundation. She also currently serves as the Board’s Treasurer and Secretary. She has a background in computational chemistry. During her postdoc years, she developed a passion for open science and research infrastructure. She is particularly interested in collaboration and coordination of efforts, and how to make the research infrastructure more robust, sustainable and accessible. Karmen was the project manager for the Open Force Field Initiative before stepping into the role of OMSF Executive Director.
is a leading figure in AI/ML for biomolecular drug discovery in the UK and globally. She leads the Oxford Protein Informatics Group (OPIG) and serves as Executive Chair of the Engineering and Physical Sciences Research Council (EPSRC), and was previously Chief Scientist at Exscientia. She has administered numerous large, highly successful projects to accelerate drug discovery.
is an associate professor in the Department of Biochemistry at the University of Washington School of Medicine. His group is focused on computational methods development for problems is structural biology, particularly in the development of machine learning methods for biomolecular structure prediction and design, methods for prediction of protein-ligand interactions, and methods for structure determination guided by sparse experimental data.
joined Zeneca Pharmaceuticals as a medicinal chemistry team leader. He co-developed matched molecular pair tools to enhance medicinal chemistry strategies. In 2012, he co-founded MedChemica Ltd. He is an inventor on 18 patents, has authored over 30 articles and a textbook. He has contributed to four projects that have advanced to clinical development including capivasertib. He was Design Team Leader for the COVID Moonshot project, leading to multiple compounds entering pre-clinical development and head of Lead Optimisation at the NIH ASAP consortium.
is a medicinal chemist who has contributed to nine marketed drugs and several clinical candidates, including treatments for HIV, hepatitis C, cystic fibrosis, and glaucoma. He currently serves as interim Chief Scientific Officer and board member at Dewpoint Therapeutics and is a senior lecturer at MIT. Previously, he was Chief Technology Officer at Vertex Pharmaceuticals, where he led the development of key drugs such as Incivek, Agenerase, Lexiva, and the cystic fibrosis portfolio. He holds a Ph.D. in organic chemistry from Yale and is a co-inventor on over 50 patents.
is head of the industrial liaison group at Diamond. She established the group at the start of Diamond operations with a focus initially on providing access to Diamond’s macromolecular crystallography infrastructure. She has since extended the group activities to provide industrial users with access to Diamond’s extensive synchrotron and CryoEM capabilities. She is strategic lead for engaging with external partners fostering collaborations across all sectors of the scientific community.
is Professor of Structural Biology at the University of Oxford. He has made major contributions to virus structure and function, including solving the structures of a wide range of viruses, including a number of important human and animal pathogens. He has been a driving force behind the establishment of key structural biology infrastructure across the UK and Europe, notably through the establishment of INSTRUCT-ERIC, the Division of structural biology at the University of Oxford and his leadership at Diamond Light Source.
is a senior scientist at EMBL and team leader for the Protein Data Bank in Europe (PDBe). He has over two decades of experience in making biomolecular structure data more accessible, integrated, and useful for the life sciences community. Sameer is a PI in the Worldwide Protein Data Bank (wwPDB) partnership and leads the AlphaFold Protein Structure Database, a collaboration with Google DeepMind. His research interests include structural data integration, functional annotation, and the use of AI to advance structural and computational biology.
is Director of Life Sciences at Diamond Light Source and Group leader for Bioimaging. He is a structural biologist with a strong track record in large multi-institutional collaborative research projects funded by the European Commission. He has contributed to methods for high-throughput structure determination methodology covering both instrumentation automation and data management, has a long standing interesting in bacterial and viral pathogens and has made key contributions to the COVID Moonshot project and NIH ASAP consortium.
Join our mailing list and become part of an exclusive community of researchers and investors driving a new era of AI-powered drug discovery. Be the first to access cutting-edge science, breakthrough results, and strategic insights.
